Cannabisrygning og psykoser
Jette Beier, Søren Haastrup
Nordic Journal of Psychiatry 1985 DOI: 10.3109/08039488509106157 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Retrospective review Peer reviewed |
|---|---|
| Sample size | 30 |
| Population | Patients admitted in a psychotic state to a psychiatric hospital serving a population area of 200,000, with cannabis smoking retrospectively judged as a significant factor related to the admission state |
| Duration | One year of admissions |
| Topics | Cannabis |
| Citations | 3 |
| Key findings | Of 30 patients admitted in a psychotic state with cannabis smoking judged a significant factor, 2 had no diagnosis other than toxic psychosis, 12 were diagnosed schizophrenic, 5 borderline, 5 with personality disorder, and 6 with an unspecified character neurotic disorder; 27 were male. The authors conclude with some uncertainty that at least 15 persons per 100,000 population are admitted annually because of cannabis-provoked psychosis, and they point to younger single males diagnosed with schizophrenia, borderline, or personality disorder as a risk group. |
Abstract
This study illustrates the frequency and nature of serious psychiatric complications related to cannabis abuse. A review of recent years' literature referring to this subject leads to the conclusion that it is commonly considered that in rare cases cannabis can induce acute toxic psychosis in premorbidly healthy persons, and that it can also induce aggravation of chronically psychotic respective borderline states. A retrospective review of one years' admissions to a psychiatric hospital in a population area of 200,000 shows that 30 patients fulfilled the criteria of the study: (1) admission in a psychotic state; (2) cannabis smoking retrospectively judged as a significant factor related to the state at admission. Two patients did not have a psychiatric diagnosis other than toxic psychosis, 12 were diagnosed schizophrenic, 5 were borderline, 5 had personality disorder, and 6 an unspecified character neurotic disorder. Out of these 30 patients 27 were male. With some uncertainty the following is concluded: Of a population of 100,000 annually at least 15 persons are admitted to a psychiatric hospital because of a cannabis-provoked psychosis. A risk group is pointed out, namely younger single males who are diagnosed schizophrenic, borderline, or having a personality disorder. It is recommended that this group in particular is warned against cannabis smoking.
Comparable studies
Other observational and cohort studies on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| High-potency cannabis and the risk of psychosis People with first episode of psychosis and healthy controls from the local population | 2009 | Case-control study | n = 454 |
| Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada Rural aboriginal population | 2013 | Observational study | |
| Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) Otherwise healthy young people | 2000 | Observational | |
| Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study Individuals from the general population in Germany aged 14-24 at baseline | 2011 | Observational cohort | n = 1,923 |
| Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases Patients treated for cannabis-induced psychotic symptoms in Denmark between 1994 and... | 2005 | Observational cohort | n = 535 |
Citations in the library
Cites 5
- Marihuanann Psychosis JAMA October 13, 1969
- Forty-Six Cases of Psychosis in Cannabis Abusers Gunila Bernhardson International Journal of the Addictions 1972
- Cannabis psychoses in south Sweden. Acta Psychiatrica Scandinavica October 1, 1982
- Cannabis psychosis and paranoid schizophrenia. Archives of General Psychiatry March 1, 1976
- Psychosis Associated with Cannabis Smoking British Journal of Addiction to Alcohol & Other Drugs September 1, 1972